Understanding the Patient Selection Process for CTCL Treatment

Name: Understanding the Patient Selection Process for CTCL Treatment
Uploaded: 2021-09-22T12:00:00.000Z
Description: Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

September 22, 2021

Video

Conference|Society of Hematologic Oncology (SOHO) Annual Meeting

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

Pharmacy Times interviewed Lauren C. Pinter-Brown, MD, FACP, professor in the Department of Dermatology and the Department of Medicine in the Division of Hematology and Oncology at UCI Health and Chao Family Comprehensive Cancer Center, on her recent presentation at the Society of Hematologic Oncology Annual Meeting 2021 conference on the treatment of advanced cutaneous T cell lymphoma (CTCL) in 2021.

During this discussion, Pinter-Brown explained whether the current advanced CTCL treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.